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OBJECTIVE: To demonstrate the role of angiogenesis in the progression of cutaneous squamous cell carcinoma.
INTRODUCTION: Angiogenesis is a pivotal phenomenon in carcinogenesis. Its time course in cutaneous squamous
cell carcinoma has not yet been fully established.
METHODS: We studied the vascular bed in 29 solar keratoses, 30 superficially invasive squamous cell carcinomas and
30 invasive squamous cell carcinomas. The Chalkley method was used to quantify the microvascular area by
comparing panendothelial (CD34) with neoangiogenesis (CD105) immunohistochemical markers. The vascular bed
from non-neoplastic adjacent skin was evaluated in 8 solar keratoses, 10 superficially invasive squamous cell
carcinomas and 10 invasive squamous cell carcinomas.
RESULTS: The microvascular area in CD105-stained specimens significantly increased in parallel with cutaneous
squamous cell carcinoma progression. However, no differences between groups were found in CD34 sections. Solar
keratosis, superficially invasive squamous cell carcinoma and invasive squamous cell carcinoma samples showed
significant increases in microvascular area for both CD34- and CD105-stained specimens compared with the
respective adjacent skin.
DISCUSSION: The angiogenic switch occurs early in the development of cutaneous squamous cell carcinoma, and the
rate of neovascularization is parallel to tumor progression. In contrast to panendothelial markers, CD105 use allows
a dynamic evaluation of tumor angiogenesis.
CONCLUSION: This study demonstrated the dependence of skin carcinogenesis on angiogenesis.
KEYWORDS: Pathologic neovascularization; CD105 antigen, human; CD34 antigen; skin neoplasms; keratosis,
actinic.
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INTRODUCTION
Non-melanoma skin cancer is the most common cancer in
humans and is more prevalent among fair-skinned indivi-
duals.1 However, if the in situ component of cutaneous
squamous cell carcinoma (CSCC), that is, solar keratosis
(SK), were accounted for in epidemiology, CSCC would be
the most frequent human malignancy.2
Although the complex events leading to cancer progres-
sion are not yet entirely clear, they certainly involve close
interactions between neoplastic cells and the microenviron-
ment.3,4 The recruitment of new capillary blood vessels
(angiogenesis) is a prerequisite for clonal expansion, tumor
growth, invasion and metastasis in most cancers.2,5 The
dependence on neovascularization for CSCC invasion
remains controversial.
A tumor vascular bed may be quantified by different
means, including the microvascular density (MVD) and
Chalkley microvascular area methods.6 The evaluation of
MVD using panendothelial markers, for example, CD34,
may assess the vascular status of a tumor bed but not its
angiogenic activity.7
CD105, also known as endoglin, is a cell membrane
glycoprotein responsible for the modulation of endothelial
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responses to transforming growth factor b (TGFb).8 Endoglin
is associated with proliferation and may be induced by
hypoxia, thus playing an important role in vascular devel-
opment and remodelling.6,8 The expression of CD105 has
been repeatedly demonstrated to be strongly positive in
tumor vessels when compared with normal tissue.9,10
The aim of this study was to quantify the vasculature at
the different stages of carcinogenesis of CSCC by comparing
panendothelial to neoangiogenesis markers.
MATERIALS AND METHODS
CSCC specimens from dorsal hands or forearms had been
routinely formalin fixed and paraffin embedded, and we
randomly retrieved those dated between 2001 and 2009
from the files of the Department of Pathology, Faculty of
Medical Sciences, University of Campinas (UNICAMP). A
total of 89 hematoxylin-eosin-stained slides were reviewed
and divided into 3 groups: 1) the in situ component, solar
keratosis (SK, N= 29); 2) superficially invasive squamous
cell carcinoma (siSCC, N=30); and 3) invasive squamous
cell carcinoma (iSCC, N=30). Because the borderline
between SK and early CSCC is not clear cut and SK satisfies
all of the histopathological criteria for CSCC, SK is
considered to be a kind of in situ CSCC.2
Tumors from patients with xeroderma pigmentosum,
albinism, arsenicism, any kind of imunosuppression, or a
history of previous radiotherapy were not included.
This study was approved by the Research Ethics
Committee of the State University of Campinas, Brazil.
Immunohistochemical staining
The following primary antibodies were used: CD34
(QBEnd-10; DAKO, Glostrup, Denmark) at a dilution of
1:150 and CD105 (SN6h; DAKO, Carpinteria, USA) at a
dilution of 1:10. All slides were incubated for 25 minutes
and 12 hours at room temperature with CD34 and CD105,
respectively. For CD34, antigen retrieval was effected using
0.25% proteinase K (DAKO, Carpinteria, USA) at 37 C˚
for 10 min. For CD105, antigen retrieval was effected using
0.4% pepsin at 37 C˚ for 30 min. CD105 sections were
also incubated with serum-free protein block (DAKO,
Carpinteria, USA) at 37 C˚ for 30 min. The EnVision Plus
polymer (DAKO, Carpinteria, USA) was used as a reaction
amplifier. Appropriate control (granulation tissue) was
included in each test. Negative control was obtained by
omitting the primary antibody. Both CD34 and CD105 are
cell membrane proteins; therefore, immunoreactivity was
considered positive when a membrane staining pattern was
found in endothelial cells.
Microvessel quantification
The microvessel area was estimated using the Chalkley
point counting system,11 a reproducible method for the
immunohistochemical evaluation of angiogenesis.12,13 Brie-
fly, a 25-point Chalkley eyepiece graticule was applied to
the areas of the tumor with the highest microvessel profiles,
called hot spots.6 The intersecting points were recorded at a
specific magnification, as was the corresponding defined
Chalkley grid area. The Chalkley count was calculated as
the mean value of three or four graticule counts.
Histological sections were blindly scanned at low
magnification (1006) by two observers to identify the hot
spots in tumor fronts, i.e., in the boundary stroma from
typical areas of the three groups. A 25-point Chalkley
eyepiece graticule was then applied to each hot spot, using a
magnification of 4006 (Chalkley grid area 0.041 mm2). The
Chalkley count (CC) was obtained by finding the mean
value of three graticule counts. Specimens with adjacent
non-neoplastic skin that exhibited sufficient stroma for the
evaluation of vascular hot spots were also studied.
Therefore, we analyzed 28 slides: eight from skin adjacent
to SK, ten from siSCC, and ten from iSCC.
Statistical analysis
The data were tested using Winstat 3.1 software (Kalmia
Company Inc, Cambridge, USA). T-test dependent and
analysis of variance (ANOVA) were used to evaluate
differences between groups.
RESULTS
Whereas the CD105 Chalkley count significantly
increased with CSCC progression from SK to iSCC
(ANOVA, P= 0.006) (Figures 1 and 2), the CD34 Chalkley
count was not correlated with tumor stage (ANOVA,
P= 0.55). In addition, the CD34 and CD105 Chalkley counts
of the advancing tumor fronts were significantly higher than
those of the respective adjacent non-neoplastic tissue (P
values in Table 1). When the Chalkley counts of adjacent
non-neoplastic tissue were compared between the groups,
no significant differences were found for either the CD34
(P = 0.44) or CD105 (P= 0.89) immunomarkers.
Endothelial cell immunoreactivity for CD105 was positive
in 28.6% (eight) of 28 adjacent non-neoplastic tissue samples
and 78.7% (70) of 89 tumor lesions. For CD34, these rates
were 96.4% and 100%, respectively.
DISCUSSION
There is an ongoing debate over the malignant nature of
SK.2,14-16 It has been estimated that 10% of SKs invade the
dermis.14 The tendency to spread, the lethal potential of
untreated lesions and the full CSCC histopathological
criteria found in SK make considering SK a type of in situ
CSCC reasonable.2 Understanding the pathophysiology of
Figure 1 - CD105 mean Chalkley counts for solar keratosis (SK),
superficially invasive squamous cell carcinoma (siSCC) and
invasive squamous cell carcinoma (iSCC).
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carcinogenesis is crucial for developing therapies for and
preventing complications of this common neoplasm.
After centuries of observation and research, the vascular
bed of tumors is still an area of interest due to its role in
malignancy progression. Several mechanisms are responsi-
ble for tumor blood supply, including angiogenesis. The
angiogenic theory supports the possibility that tumor cells
can elicit growth of new capillary endothelium. A positive
balance between angiogenesis inducers and countervailing
inhibitors activates the ‘‘angiogenic switch,’’ the transfor-
mation of a quiescent vascular bed into a proliferating one.5
The quantification of vasculature in human tumors began
in 1991, when vessels were immunohistochemically high-
lighted with antibodies to factor VIII-related antigen.11 Since
then, several immunohistochemical markers have been used
to stain and study vessels.6,14 However, panendothelial
markers, such as CD34, CD31, factor VIII and von
Willebrand factor, do not distinguish between small and
large vessels.17 One alternative to panendothelial markers is
CD105, which is over-expressed in proliferating endothelial
cells and is strongly up-regulated in the endothelium of
various neoplastic tissues compared with normal ones.8-10,18
Our results reinforced the neoangiogenic character of this
marker because CD105 expression was less evident in
vessels from chronic sun-damaged adjacent non-neoplastic
tissue (28.6%) than in those from the tumor front (78.7%)
(Figure 2), in contrast to the indiscriminate immunoreactiv-
ity found in CD34 samples.
Among the different techniques used for the immunohis-
tochemical study of angiogenesis, we chose the Chalkley
method because it is considered to be the most accurate.6,12
Specifically, the Chalkley method abolishes the observer-
dependent judgment in quantifying adjoining immunos-
tained structures, such as deciding whether a vessel is vessel
single or two distinct blood vessels.13 Whereas early CSCC
cells distribute parallel to the epidermis, the developed
CSCC cells spread out though the dermis, and vessels
accompany the tumor architecture. Because the Chalkley
method considers intersecting points within the circumfer-
ential area of the ocular, the distribution of the structures
influences the count. Of the magnifications normally used
(200, 250 and 4006),6,18 we considered it more reliable to use
the highest (4006) so that vessels from different groups
could be distributed in the circumference.
In this study, vessels were assessed in the stroma of the
tumor front, regardless of whether they were intra- or peri-
tumoral, because islands of desmoplasia and angiogenesis
are created at sites where multiple cutaneous carcinoma
protrusions invade the dermis.
Angiogenesis can be activated at different stages of tumor
progression.4 For example, Smith-McCune et al. studied the
multi-stage progression of invasive CSCC in transgenic mice
and concluded that the angiogenic switch occurs during the
premalignant stages of tumorigenesis.19 In addition,
Coussen et al. proposed that the disruption of the stromal
architecture in the dermis at the dysplastic stage could be
related to the release of matrix-bound heparin-binding
growth factors and the consequent activation of angiogen-
esis.20
The data regarding human CSCC are controversial in part
because researchers evaluate angiogenesis in different ways.
For example, Strieth et al. analyzed mean vascular density in
CD31-immunostained vessels from normal skin, SK, hyper-
trophic SK, and early- and late-stage CSCC samples via
computer-assisted imagery.21 Only late stage CSCCs exhib-
ited a significant increase in vascularization using thismethod.
In contrast, Nijsten et al. compared maximum andmean CD34
Chalkley counts in vascular hot spots of normal skin, SK and
iSCC and found significantly higher counts in both SK and
iSCC than in normal skin.22 This group also studied the active
angiogenesis rate through the endothelial cell proliferation
(ECP) fraction using double labeling of Ki-67/CD34 endothe-
lial cells. The ECP was found to be significantly increased and
was parallel to CSCC progression.22
The present study showed that the angiogenic switch occurs
early in the development of CSCC, which was demonstrated
using both panendothelial and neoangiogenesis markers.
Figure 2 - Vascular hot spots in CD105-stained adjacent non-
neoplastic skin (A), SK (B), siSCC (C), and iSCC (D).
Table 1 - Mean CD34 and CD105 Chalkley counts in
stroma from tumor fronts and adjacent non-neoplastic
skin.
CD34 CC CD105 CC
Adjacent
skin
Tumor
front P
Adjacent
skin
Tumor
front P
SK 1.91 3.25 0.049 0.08 1.66 0.046
siSCC 2.06 3.50 0.016 0.36 2.46 0.0008
iSCC 2.16 3.96 0.028 0.46 3.73 0.001
CC: mean Chalkley count, SK: solar keratosis, siSCC: superficially invasive
squamous cell carcinoma, iSCC: invasive squamous cell carcinoma.
Differences between tumor front and adjacent skin were evaluated by T-
test dependent.
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Using the panendothelial CD34 stain, no differences were
found in themicrovascular area between the different stages of
CSCC. However, the CD105 stain revealed an induction of
newly formed vessels that accompany the progression of
CSCC. Therefore, Nijsten’s data22 were corroborated by our
findings, which emphasizes the necessity of assessing tumor
angiogenesis through active angiogenesis markers (ECP and
CD105).
It has been proposed that angiogenesis onset occurs not
only for metabolic supply but also for the establishment of
invasion pathways by producing proteases and/or for
guiding tumor cells.4,21 Because SKs are limited lesions,
angiogenesis induction in this stage supports their invasive
carcinomatous behavior.
A lower MVD has been found in neoplastic tissue in
glioblastomas and renal, colon and mammary carcinomas
compared with their respective normal tissues.5 As a result,
Eberhard et al. and Hlatky et al. have suggested that
techniques for assessing microvessel density using pan-
endothelial markers estimate the vascular bed amount of a
tissue but not the angiogenic status, that is, the rate of
evolving neovasculature.5,23 Because neo-angiogenesis mar-
kers allow the dynamic evaluation of tumor-dependent
angiogenesis, they should be considered for assessing
angiogenic status in the future.
CONCLUSION
The dependence of skin carcinogenesis on angiogenesis
demonstrated in this study is useful for understanding
CSCC evolution and metastatic dissemination and for the
development of new therapeutic strategies, such as anti-
angiogenic therapies, that specifically target CD105.
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